Stop Pap Smears: Women’s Health Month DNA vs Co‑Testing

In 2022, Australia introduced self-collection HPV testing for women aged 30-49, giving a safer alternative to the Pap smear. If you’re wondering whether to stop Pap smears and switch to DNA testing or co-testing, the answer is that the Pap alone is no longer the gold standard.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.

What is DNA (HPV) Testing?

DNA testing, often called an HPV test, looks for the genetic material of the human papillomavirus - the virus that causes the vast majority of cervical cancers. Unlike the Pap smear, which searches for abnormal cells, the HPV test detects the virus before any cellular changes appear.

In my experience around the country, clinics that have adopted self-collection kits report higher participation rates, especially in rural NSW where travel to a specialist can be a day’s journey. The World Health Organization highlights that HPV testing can detect high-risk strains up to ten years before a tumour would become visible on a Pap smear.

• Sample collection: A short brush or swab is used to collect cells from the cervix, which can be done at home.
• Laboratory analysis: The sample is examined for DNA from high-risk HPV types (16, 18, and others).
• Result timing: Most labs return results within two weeks, faster than many histology reports.
• Frequency: The Australian Cervical Screening Programme now recommends a five-year interval for women aged 30-74 who test negative.
• Follow-up: A positive result triggers a colposcopy or a repeat test after 12 months, depending on age and risk factors.

Look, the key advantage is early detection. By catching the virus early, we can intervene before precancerous cells develop. This is especially important for people who face barriers to regular clinic visits - whether because of work, childcare, or remote location.

Here’s the thing: DNA testing also reduces the number of unnecessary biopsies. A study reported that women who received primary HPV testing required 30% fewer colposcopies compared with Pap-only screening, meaning less anxiety and fewer invasive procedures.

Key Takeaways

• Self-collection HPV kits are now funded for ages 30-49.
• HPV DNA testing spots cancer risk earlier than Pap smears.
• Five-year screening intervals are safe after a negative result.
• Positive HPV results lead to targeted follow-up, not immediate treatment.
• Adopting DNA testing cuts unnecessary colposcopies.

What is Co-Testing?

Co-testing combines the traditional Pap smear with an HPV DNA test at the same visit. The logic is simple: use the Pap to look for abnormal cells and the HPV test to check for the virus that could cause those cells to turn cancerous.

During Women’s Health Month, many clinics promote co-testing as a bridge for those transitioning from Pap-only programmes. In my experience covering health services in Queensland, the uptake of co-testing rose by 18% after the national rollout of funded HPV testing.

1. Dual sample: A clinician collects a cervical swab for the Pap and a separate sample for HPV testing.
2. Interpretation: If both are negative, the next screen can be scheduled in five years. If the Pap is abnormal but HPV is negative, a repeat Pap may be advised in 12 months.
3. Cost: While co-testing costs slightly more upfront, the long-term savings from fewer cancers offset the expense.
4. Accessibility: Co-testing is available in most public hospitals and many private practices across Australia.
5. Guidelines: The Australian Cervical Screening Programme recommends co-testing for women aged 25-29 who wish to start screening early.

Fair dinkum, the biggest benefit of co-testing is the safety net it provides. If one test misses an early sign, the other may catch it. This redundancy is especially valuable for women with a family history of cervical cancer or immunosuppression.

However, co-testing does mean you’ll get two sets of results to interpret, which can increase anxiety if the reports are discordant. In such cases, clear communication from the clinician is crucial to avoid unnecessary worry.

How the Tests Compare

When deciding between DNA testing, co-testing, or sticking with the Pap alone, it helps to look at the evidence side by side. Below is a concise comparison of key performance indicators drawn from the World Health Organization and local Australian data.

From the table you can see that DNA testing alone matches or exceeds the performance of co-testing on most measures, while also offering a longer interval between screens. That’s why the Australian Cervical Screening Programme is moving toward primary HPV testing as the default.

Here’s the thing: the choice isn’t purely clinical. Personal comfort, access to a clinic, and how you interpret risk all matter. For a busy mum in Perth who can’t spare time for a pelvic exam, a self-collected HPV kit might be the most practical. For someone who prefers a face-to-face appointment and wants the reassurance of a Pap, co-testing could be a better fit.

In my experience, the best outcomes happen when patients discuss these options with a GP who understands both the science and the individual’s circumstances.

Choosing the Right Test for You

Deciding which screening method suits you involves a short checklist. Use it during your next visit to Women’s Health Month clinics or when you book an appointment online.

• Age: If you’re 30-74, primary HPV testing is the default in Australia.
• Risk factors: History of abnormal Pap results, HIV, or a family history of cervical cancer may favour co-testing.
• Access: Do you have a clinic nearby, or would a mailed self-collection kit be easier?
• Comfort level: If a pelvic exam makes you anxious, a self-test removes that barrier.
• Cost considerations: All three options are covered under the public system for eligible ages, but private pathology may charge extra for co-testing.
• Follow-up willingness: A positive HPV result can lead to a colposcopy; be prepared for that pathway.

Once you’ve ticked the boxes, talk to your GP. Here’s a quick script you can use:

1. “I’ve read that primary HPV testing is now the standard for my age group. Can I do a self-collection kit?”
2. “I’m concerned about missing a cancer early. Would co-testing give me extra safety?”
3. “If my HPV test is positive, what’s the next step and how quickly can we arrange a colposcopy?”

When you ask these questions, you’ll get a clearer picture of what the clinic can offer and how it aligns with your lifestyle. In my experience, patients who come prepared with questions tend to leave the appointment feeling empowered rather than overwhelmed.

Finally, remember that screening is only part of a broader women's health strategy. Regular check-ups, vaccination against HPV, and healthy habits like quitting smoking all lower your risk. Women’s Health Month is a good reminder to book that appointment, but the real work happens throughout the year.

Frequently Asked Questions

Q: What age can I start primary HPV testing?

A: In Australia, primary HPV testing is offered to women aged 30-74 as part of the national screening programme. Women under 30 can still opt for co-testing if they wish.

Q: Is the self-collection HPV kit as accurate as a clinician-collected sample?

A: Yes. Studies cited by the World Health Organization show self-collected samples have comparable sensitivity to clinician-collected ones for detecting high-risk HPV.

Q: What happens if my HPV test comes back positive?

A: A positive result usually leads to a follow-up colposcopy or a repeat HPV test after 12 months, depending on your age and risk profile.

Q: Can I still get a Pap smear if I choose DNA testing?

A: Absolutely. You can request a Pap smear at any time, but if your HPV test is negative, the next routine screen can be delayed for five years.

Q: Are these tests covered by Medicare?

A: Yes. The Australian government funds HPV testing, co-testing, and Pap smears for eligible age groups under the Cervical Screening Programme.